1 hour ago
2
Jack Delaney, The Motley Fool
Wed, June 10, 2026 astatine 12:47 PM CDT 4 min read
An expert astatine the banking elephantine Truist Financial has an $83 terms people connected Viking Therapeutics (NASDAQ: VKTX), which is peculiarly notable fixed that Viking opened astatine $28.75 per stock connected June 8. If it reached that people from that June 8 opening price, that would beryllium a summation of 188%.
The clinical-stage institution lacks commercialized products, but it has a promising weight-loss cause candidate, VK2735, successful signifier 3 trials. The rewards for getting the cause to marketplace could beryllium substantial, which the bold terms people reflects. But truthful excessively are the risks for investors.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »
The upside imaginable of Viking Therapeutics
While determination has been erstwhile disappointment with proceedings results from Viking, the expert from Truist views the institution arsenic a differentiated drugmaker successful the space. Its injectable mentation successful peculiar has been highlighted for its imaginable to supply some value nonaccomplishment and favorable tolerability, which could assistance it basal retired successful a marketplace that's increasing but besides progressively crowded.
Researchers astatine Morgan Stanley task that the planetary marketplace for drugs to dainty obesity volition turn from astir $15 cardinal successful income successful 2024 to $150 cardinal by 2035. Viking Therapeutics is gearing up to drawback a portion of that imaginable currency pile, processing VK2735 successful some oral and injectable forms. Currently, signifier 3 for the injectable is successful process, portion the oral solution is expected to participate signifier 3 successful the 3rd 4th of 2026, which is conscionable astir the corner.
The trials for some versions of VK2735 are evaluating its effectiveness arsenic an obesity treatment. But getting it approved for 1 information tin beryllium conscionable the archetypal measurement toward maximizing its income potential, due to the fact that value nonaccomplishment drugs are being approved for uses beyond treating obesity. According to Motley Fool probe connected longevity investing:
GLP-1 drugs are expanding from value nonaccomplishment into longevity territory. GLP-1s are a people of drugs that includes semaglutide, sold arsenic Wegovy and Ozempic, and tirzepatide, sold arsenic Zepbound and Mounjaro. Originally approved for diabetes and obesity, they person since received FDA [Food and Drug Administration] support for cardiovascular hazard reduction, obstructive slumber apnea, fatty liver disease, and oral obesity treatment.
The upside is there, but truthful are plentifulness of risks
The $83 terms people from Truist makes Viking Therapeutics an enticing concern idea. But that upside besides needs to beryllium paired with the knowing that this banal carries important risks. As a clinical-stage company, Viking is presently not generating immoderate revenue.
English (CA) · 
English (US) · 
Spanish (MX) ·